By VETTAPHARMA reporter – Veera Rodrigues: Amgen is expanding its U.S. manufacturing footprint with an additional $300 million investment, bringing its total manufacturing investments to nearly $2 billion over the last year, reflecting a sustained push to strengthen domestic production capacity and supply reliability.
The latest capital allocation is directed toward enhancing U.S.-based production capabilities, adopting next-generation manufacturing technologies, and reinforcing the consistency of medicine supply for patients, indicating a continued prioritization of resilient infrastructure.
This move builds on a broader series of manufacturing investments over the past year, including $650 million in Puerto Rico, $900 million in Ohio, and more than $1.5 billion in North Carolina, alongside a $600 million investment in a science and innovation center in California.
Taken together, the cumulative investments underline a clear strategic direction toward reinforcing U.S. operations, advancing biologics manufacturing capabilities, and ensuring long-term scalability of supply amid growing demand.
A stronger U.S.-based manufacturing network directly translates to improved medicine availability and supply continuity, reducing the risk of shortages and delays. Increased investment in advanced technologies also suggests potential improvements in production efficiency and quality, which can support consistent patient access to critical biologic therapies.
The nearly $2 billion cumulative investment signals a long-term commitment to vertical integration and supply chain control. By expanding domestic capabilities, Amgen is positioning itself to better manage production risks, respond faster to demand fluctuations, and support future pipeline growth, particularly in complex biologics.
This scale of investment reinforces a broader industry shift toward localized manufacturing and supply chain resilience, especially in the U.S. Amgen’s multi-site expansion across Puerto Rico, Ohio, North Carolina, and California highlights a strategic effort to stay competitive with peers investing heavily in biologics manufacturing infrastructure.
- $300 million (latest investment): Incremental capacity and technology upgrade signal
- ~$2 billion (total in one year): Aggressive scale-up of manufacturing footprint
- $650M + $900M + $1.5B + $600M: Multi-location diversification reduces operational risk and strengthens national supply coverage
